HASBROUCK HEIGHTS, N.J., May 22, 2018 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX ) is pleased to report on a successful symposium discussing Nymox’s lead product candidate Fexapotide Triflutate (FT) as a novel therapeutic option in BPH at the Annual Meeting of the American Urological Association in San Francisco, this past weekend.
Dr. Ronald Tutrone of Chesapeake Urology Research Associates, Baltimore MD, and a principal investigator in the trials, chaired the meeting and presented clinically relevant therapeutic highlights from the trials. Following Dr. Tutrone’s presentation, other panel members commented on their positive experiences with the drug and answered questions from the audience. The panel members included Dr. Mohamed Bidair, San Diego CA; Dr. Ivan Grunberger, New York NY; Dr. Alan Hay, Salem OR and Dr. Susan Kalota, Tucson AZ.
Dr. Tutrone said, "FT is a safe, effective and much needed treatment for men who have BPH. This is a less than 5 minute treatment that every urologist can easily integrate into their management of their BPH patients."
Dr. Hay commented: ”When and where FT is approved, I anticipate it will quickly become the initial choice for all men with BPH/LUTS. It is safe and simple to deliver. A single injection has symptom relief on the order of current oral medications; 2 injections give symptom relief on the order of surgery. It is hard to think of a patient with BPH/LUTS who wouldn’t benefit from up-front FT injection no matter what else is planned for their disease. The ease of injection and the impeccable safety profile further reinforce that point.”
Randall Lanham, one of Nymox's Directors, also commented: “Having been with the Company for many years, it is now very gratifying to witness the very positive responses we see from an ever-larger audience of clinicians across the country. Investigators have now presented data at five regional AUA meetings in addition to this weekend’s national meeting and there was a detailed peer reviewed publication of Phase 3 clinical trial results earlier this year in the World Journal of Urology. These are important milestones and events for the development of Fexapotide."
Dr Grunberger added, "The positive response of the AUA attendees to the data confirmed my belief that Fexapotide Triflutate has the potential to position itself as a first line therapy for BPH once approved."
Dr Kalota said, "I am very excited about the data and look forward to the future when I can freely offer this to my patients. The data has shown efficacy and safety, and my personal experience with the injections demonstrated the ease of injection and acceptability to the patients."
Dr Bidair added, "I believe that the ease of administration of FT and virtual lack of safety concerns and side effects will make it a significant addition to our armamentarium for treating BPH."
Nymox's fexapotide has been shown to produce long-term improvements in lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH), a problem that afflicts an estimated 100 million or more men in the world. Fexapotide does not cause the annoying side effects and risks found with available treatments for BPH and has also been shown to lower the occurrence of surgery for BPH. Fexapotide is also in development for low grade prostate cancer.
For more information please contact info@nymox.com or 800-936-9669.
Forward Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of Fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for Fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox's regulatory filings, Nymox's substantial dependence on Fexapotide, Nymox's commercialization plans and efforts and other matters that could affect the availability or commercial potential of Fexapotide. Nymox undertakes no obligation to update or revise any forward looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox's current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2017, and its Quarterly Reports.
For Further Information Contact: Erik Danielsen Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com
